Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ComFluCOV
ISRCTN14391248Phase 4Completed
- Sponsor
- University Hospitals Bristol and Weston NHS Foundation Trust
- Start
- Mar 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
01
Overview
Phase 4, randomised, double-blind trial of influenza vaccine (cell-based), Fluzone Trivalent, ChAdOx1 nCoV-19, tozinameran and sodium chloride in influenza and coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University Hospitals Bristol and Weston NHS Foundation Trust. Primary endpoint: Incidence of at least one solicited systemic reaction. Started Mar 2021; status: completed.
02
Drugs
influenza vaccine (cell-based)Fluzone TrivalentChAdOx1 nCoV-19tozinameransodium chloride
03
Conditions
influenzacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ISRCTN14391248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14391248.